Efficacy and Safety of Less Invasive Surfactant Administration Combined with Budesonide and Supported by Nasal Intermittent Positive Pres-sure Ventilation in Preterm Infants with Respiratory Distress Syndrome:a Clinical Research
10.11969/j.issn.1673-548X.2025.06.022
- VernacularTitle:经鼻间歇正压通气下微创肺表面活性物质给药技术联合布地奈德治疗早产儿呼吸窘迫综合征的疗效及安全性研究
- Author:
Xueli TU
1
;
Bao JIN
;
Xueqi CHEN
Author Information
1. 221000 徐州医科大学徐州临床学院
- Publication Type:Journal Article
- Keywords:
Less invasive surfactant administration;
Budesonide;
Non-invasive respiratory support;
Newborn respiratory distress syndrome;
Preterm
- From:
Journal of Medical Research
2025;54(6):121-126
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the efficacy and safety of less invasive surfactant administration(LISA)combined with budesonide and supported by nasal intermittent positive pressure ventilation(NIPPV)in preterm infants with respiratory distress syndrome(RDS).Methods Premature infants with RDS at the gestational age of 26-32 weeks in the neonatal ward of Xuzhou Central Hospital from Feb-ruary 2022 to March 2024 were divided into the observation group and the control group in this prospective randomized controlled trial.The control group suspended nasal continuous positive airway pressure(NCPAP),they were intubated and infused with PS into the lung through endotracheal tube and extubated(INSURE),then continued to receive NCPAP.In the observation group,a LISA tube was insert-ed through the vocal cords under direct vision with direct laryngoscope,then infused pulmonary surfactant(PS)and budesonide into the lung when NIPPV ventilation was applied.The results of blood gas analysis at 1h and 6h after intratracheal instillation of PS,medication administration,clinical efficacy,related complications of budesonide,bronchopulmonary dysplasia(BPD)were compared between the two groups.Results A total of 126 preterm infants with RDS were enrolled in the study,including 65 in the observation group and 61 in the control group.The incidence of regurgitation in the observation group were lower than those in the control group[(10.8％(7/65)vs 24.6％(15/61)],and the differences were statistically significant(P＜0.05).The PaO2/FiO2(P/F)in the observation group at 1h and 6h were higher than those in the control group,while PaCO2were lower than those in the control group,and the differences were statis-tically significant(all P＜0.05).The duration of non-invasive respiratory support(11.4±4.6 days vs 15.9±5.6 days),total oxygen inhaling(14.9±6.9 days vs 21.2±8.5 days),failure rate of machine withdrawal[(10.8％(7/65)vs 24.6％(15/61)],the rate of tracheal intubation within 72h[9.2％(6/65)vs 23.0％(14/61)],and re-administration of PS[18.5％(12/65)vs 34.4％(21/61)],the times of apnea[9.0(3.0-25.0)times vs 17.0(5.0-29.0)times]in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).The occurrence of BPD in the observational group were lower than those in the control group[15.4％(10/65)vs 34.4％(21/61)](P＜0.05).There were no significant differences between two groups in the related complications of budesonide(all P＞0.05).Conclusion LISA combined with budesonide and supported by NIPPV can effectively improve oxygenation,shorten the duration of non-invasive respiratory support,reduce the mechanical ventilation rate,and reduce the incidence of BPD in the treatment of premature infants with RDS at the gestational age of 26-32 weeks.
